| SpyGlass Pharma, Inc. |
Director |
Common Stock |
2,187,513 |
$60,878,487 |
$27.83 |
09 Feb 2026 |
Indirect |
| CVRx, Inc. |
Director |
Common Stock |
1,829,022 |
$33,937,320 |
$18.55 |
02 Jul 2021 |
Indirect |
| CVRx, Inc. |
Director |
Stock Option (right to buy) |
10,382 |
$53,374 |
$5.14 |
29 Jun 2021 |
Direct |
| SHOULDER INNOVATIONS, INC. |
Director, 10%+ Owner |
Common Stock |
2,380,482 |
|
|
01 Aug 2025 |
Indirect |
| SpyGlass Pharma, Inc. |
Director |
Stock Option (right to buy) |
27,400 |
|
|
05 Feb 2026 |
Direct |
| SHOULDER INNOVATIONS, INC. |
Director, 10%+ Owner |
Common Stock |
7,666 |
|
|
01 Aug 2025 |
Direct |
| CVRx, Inc. |
Director |
Series G Preferred Stock |
0 |
|
|
02 Jul 2021 |
Indirect |
| SHOULDER INNOVATIONS, INC. |
Director, 10%+ Owner |
Series D Convertible Preferred Stock |
0 |
|
|
01 Aug 2025 |
Indirect |
| SHOULDER INNOVATIONS, INC. |
Director, 10%+ Owner |
Series E Convertible Preferred Stock |
0 |
|
|
01 Aug 2025 |
Indirect |
| SpyGlass Pharma, Inc. |
Director |
Series D Preferred Stock |
0 |
|
|
09 Feb 2026 |
Indirect |